Dr. Dae Wook Lee is a Medical Director of Novartis Korea in Cardiology, Renal, Metabolism, Neuroscience and Gene Therapy. He was Head of Medical Portfolio Management in Rare disease, Gastroenterology, PDT, Neuroscience and New Molecular entities from the Asia-Pacific Region of Takeda Pharmaceutical Ltd Pte. Dae Wook Lee obtained his Medical Degree from the University of Warwick, U.K. awarded MbChB Medicine & Surgery, and completed MSC Genetic Epidemiology at the Medical Research Unit in the University of Sheffield, U.K with an additional BSc Biomedical Science degree. He also holds an Executive Master of Business Administration (MBA) from Harris College of Business, Faulkner University in North Alabama in U.S. Dae Wook received the Best Research Award in the International Research Awards of Cardiology and Cardiovascular Medicine in 2022.

Dr. Dae Wook Lee’s main clinical research interests lie in genetics and novel medical statistical analysis of Rare Diseases including Cardiology, Rare Hematology, Rare Metabolic Diseases including Fabry & Gaucher’s Disease, Rare Immunology including Hereditary AngioEdema (HAE), etiology and pathophysiology of inflammatory bowel disease (IBD), and Rare Neuroscience disease including Paediatric Epilepsy and Narcolepsy Type 1. One of his recent publications includes Network Meta-analysis of Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients, and Retrospective analysis of Ulcerative Colitis Real-world Evidence implementing exploratory Propensity Score Matching (PSM) Analysis. Dr. Dae Wook Lee is also a member of Korean Society of Pharmaceutical Medicine (KSPM).